anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
sertraline is indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults.

The efficacy of sertraline in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY).

The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant.

The effectiveness of sertraline in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
Nuclear export protein-1 is the main transporter protein for leucine-rich proteins to enter the cytoplasm from the nucleus through the nuclear pore complex, which is overexpressed in malignant tumor cells. Studies have shown that Selinexor inhibits the nuclear export of viral mRNA such as EBV, and has good therapeutic potential for NKTCL. Selinexor combined with pemaspartase, dexamethasone and sequential radiotherapy may be the golden choice for early NK/T cell lymphoma, improving the local control rate of the disease and improving the overall prognosis of NK/T cell lymphoma.
Methods for planning, predictive modeling, and monitoring therapies for pulmonary diseases are provided. In some embodiments, a method for planning a treatment for a patient having a pulmonary disease includes receiving patient data including computed tomography (CT) data of a lung of the patient. The method can include generating a set of lung metrics by inputting the patient data into a first machine learning algorithm. The method can also include predicting a response of the patient to treatment for the pulmonary disease by inputting the set of lung metrics into a second machine learning algorithm. The method can further include evaluating whether the patient is a candidate for the treatment for the pulmonary disease, based on the predicted response. The method can further include evaluating whether the patient has benefited following treatment and whether additional treatment is warranted.
The present invention discloses a novel engineered peptides P3T, P7T, P8T, P9T, P13T and P8_d1 of Seq ID No. 1 to combinations comprising one or more said peptides and compositions comprising one or more said peptides with pharmaceutically acceptable carriers and excipients and their use. The peptides and composition comprising said peptides induce autophagy by binding the protein GAPR-1 (−ve regulator of autophagy). Endogenously, GAPR-1 acts by tethering critical autophagy protein Beclin-1 (+ve regulator of autophagy) at the golgi and arrest autophagy. The peptide reported here binds GAPR-1 to free Beclin-1 and subsequently induce autophagy. The peptide can be used to induce or enhance autophagy and finds therapeutic application in a broad spectrum of disease pathologies that benefit from augmented autophagy, including obesity, diabetes, NASH, cancer, cardiomyopathy, neurodegenerative diseases, IBD and pathogenic infections.
PURPOSE:To obtain a powdery vitamin E composition usable widely in the field of drugs, foods, cosmetics, etc., having excellent dispersibility to water and fluidity, comprising vitamin E, emulsifying agent, casein or a salt thereof, gum and dextrin as essential components. CONSTITUTION:An emulsifying agent (e.g. glycerin fatty acid ester) is dissolved in vitamin E at 60-70 deg.C to give an oil phase part and casein or a salt thereof (e.g. sodium caseinate), gum (e.g. gum arabic) and dextrin are dissolved in water at 60-70 deg.C to give a water phase part. Then the water phase part is blended with the oil phase part, emulsified and dried to give the aimed substance. The amount of the emulsifying agent is <=5wt.% based on vitamin E and total amounts of the casein or the salt thereof and the gum is <=200wt.%.
BACKGROUND: Post-traumatic stress disorder (PTSD) is common in adults with intellectual disabilities. Often there are additional disorders such as substance use, mood and anxiety disorders. The current study focuses on the feasibility and initial efficacy of prolonged exposure (PE) for PTSD in adults with mild intellectual disabilities. The secondary effect of PE on additional mood, anxiety and substance use disorders is also examined.
METHODS: A single case experimental design (N = 12) with an A (baseline)-B (intervention) phase including a follow-up measurement after 3 months was conducted. Time series and single time points measurements were performed.
RESULTS: Six participants dropped-out. The results showed a significant decrease in PTSD symptoms and a significant decrease in additional symptoms (social avoidance, anxiety and stress), among participants who completed treatment.
CONCLUSION: PE appears to be a feasible and effective treatment for PTSD in some adults with mild intellectual disabilities. Suggestions emerge from this study to make standard PE treatment more appropriate for adults with mild intellectual disabilities. Further research is needed to reduce drop-out in trauma treatment. Some suggestions for this are made in this study. Treatment of PTSD with PE did not appear to affect comorbid mood disorders. Further research is needed.
Ongoing and new participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (last injection at Week 44) and nucleos(t)ide analog (NA) treatment (either entecavir \[ETV\], tenofovir disoproxil or tenofovir alafenamide \[TAF\] tablets) once daily up to 48 weeks. Participants may receive optional treatment with pegylated interferon alpha-2a (PegIFN-alpha-2a) after the Week 40 for a duration of either 12 or 24 weeks at the investigator's discretion. As per amendment-5, JNJ-56136379 is no longer included as part of the study intervention and all participants are counted as single arm in each panel.
This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
Obesity is a low-grade chronic inflammation induced by the pathological expansion of adipocytes which allows the development of obesity-associated metabolic diseases like type 2 diabetes mellitus (T2D) and non-alcoholic fatty liver disease (NAFLD). However, mechanisms regulating adipocyte inflammation remain poorly understood. Here, we observed that TRIM8 was upregulated in adipocyte inflammation and insulin resistance while DUSP14 was downregulated. TRIM8 deficiency and DUSP14 over-expression decreased the level of inflammatory cytokines, increased glucose uptake content, and improved insulin signalling transduction compared to LPS treatment alone. Conversely, silencing DUSP14 increased the expression of inflammatory cytokines. It decreased the glucose uptake content and the phosphorylation level of proteins involved in insulin signalling, further impairing insulin signalling and aggravating insulin resistance. Furthermore, The decreased level of inflammatory cytokines, increased glucose uptake, and improved insulin signalling transduction caused by TRIM8 deficiency were reversed by down-regulated DUSP14. Collectively, our findings revealed that TRIM8 can regulate adipocyte inflammation and insulin resistance by regulating the MAPKs pathway which is dependent on DUSP14.
Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as a sterile solution for intravenous use in plastic containers.

Fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C13H12F2N6O and molecular weight 306.3. The structural formula is:

Fluconazole is a white crystalline solid which is slightly soluble in water and saline.

Fluconazole injection is an iso-osmotic, sterile, nonpyrogenic solution of fluconazole in a sodium chloride diluent. Each mL contains 2 mg of fluconazole and 9 mg of sodium chloride. The pH ranges from 4.0 to 8.0 in the sodium chloride diluent. Injection volume of 50mL packaged in plastic containers.

The plastic container is fabricated from a specially formulated polyvinyl chloride. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexylphthalate (DEHP), up to 5 parts per million. However, the suitability of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
Epidermal growth factor receptor Tyrosine kinase inhibitor (EGFR TKI) have been approved to treat NSCLC harboring EGFR mutation as first-line therapy. However, a large proportion of patients would become acquired resistant of EGFR-TKI after about one year although initially sensitivity. Previous studies demonstrated that the anti-angiogenesis combined with EGFR-TKI in slow-progressed EGFR mutation-positive non-small cell lung cancer achieved good efficacy and disease control rates, prolonged the progression free survival. The present study is aim to expand the number of samples to monitor resistance-related genes and tumor cells. Furthermore, to investigate the mechanism of anti-angiogenesis combine with EGFR-TKI and provide the theory for the use and promotion of clinically protocols. In this study, the primary objective is the objective response rates and the secondary goal are disease control rates, overall survival, progression free survival and drug safety.
Flowback aid mixtures and oil-in-water microemulsions produced by combining an aqueous brine with the flowback aid mixtures are disclosed. The flowback aid mixture comprises an oil, a fatty alcohol ethoxylate, and a quaternized fatty amine ethoxylate. The amount of oil is less than or equal to 12 wt.% based on the amount of flowback aid mixture. The microemulsions have a surface tension at 25Â°C less than 30 mN/m and a Z-average particle size as determined by dynamic light scattering at 25Â°C of less than or equal to 10 nm. Also disclosed are processes that utilize the flowback aid mixtures. In one process, the mixture is introduced into a subterranean formation and is combined prior to or during its introduction into the formation with a formation brine, process water, or both to give the microemulsion. In one hydraulic fracturing process for recovering gas, oil, or both, a fracturing fluid and the flowback aid are co-injected into a subterranean formation to give the microemulsion.
Background: Epilepsy is a chronic neurological disorder characterized by recurrent epileptic attacks and researches have reported that the relation between epilepsy and the reproductive dysfunction is not yet completely understood. Seizures are linked with sexual dysfunction as part of the disease pathophysiology in these patients. Through epileptic discharge, hypothalamus receives signals from hippocampus, amygdala and cerebral cortex. Hypothalamic-pituitary axis signaling changes is leading to sex hormones release including follicle stimulating hormones and luteinizing hormone changes.

However, the available antiepileptic drugs (AED) have not yet been proven to have negative impacts on sexual function. Evaluation of AED induced sexual dysfunction is complicated, less than clear, and is hard to find. Sex hormone levels can be changed due to AEDs which are the cause of sexual dysfunction and reproductive disorders Different antiepileptic drugs are responsible for reproductive dysfunction in male epileptic patients. The aim of this study is to evaluate the effect of valproate versus levetiracetam as a monotherapy on males' sex hormones and sperm parameters in newly diagnosed epilepsy. Methods: This comparative study included 50 newly diagnosed epileptic male participants from outpatient clinic of Neurology department of Zagazig University Hospitals. All participants were subjected to complete general and neurological examination, Doppler ultrasonography of the testis, pre and post treatment serum sex hormone assay and semen analysis. Post- treatment re- evaluation check point was determined if eight weeks have passed after the last seizures. This study included two groups, group I: 25 participants, were treated by valproate (VPA) as a monotherapy till became seizure free at the last 8-weeks before post treatment check-point, with ages ranged from 18-43 years. Group II: 25 participants were treated by levetiracetam (LEV) with the same regimens of valproate as a monotherapy, with ages ranged from 20-45 years.
Currently, the oncogenic mechanism of endoplasmic reticulum stress-CAF (ERS-CAF) subpopulation in chordoma remains unknown. Here, single-cell RNA sequencing, spatial transcriptomics, GeoMx Digital Spatial Profiler, data-independent acquisition proteomics, bulk RNA-seq, and multiplexed quantitative immunofluorescence are used to unveil the precise molecular mechanism of how ERS-CAF affected chordoma progression. Results show that hypoxic microenvironment reprograms CAFs into ERS-CAF subtype. Mechanistically, this occurrs via hypoxia-mediated transcriptional upregulation of IER2. Overexpression of IER2 in CAFs promotes chordoma progression, which can be impeded by IER2 knockdown or use of ERS inhibitors. IER2 also induces expression of ERS-CAF marker genes and results in production of a pro-tumorigenic paracrine GMFG signaling, which exert its biological function via directly binding to ITGB1 on tumor cells. ITGB1 inhibition attenuates tumor malignant progression, which can be partially reversed by exogenous GMFG intervention. Further analyses reveal a positive correlation between ITGB1high tumor cell counts and SPP1+ macrophage density, as well as the spatial proximity of these two cell types. Clinically, a significant correlation of high IER2/ITGB1 expression with tumor aggressive phenotype and poor patient survival is observed. Collectively, the findings suggest that ERS-CAF regulates SPP1+ macrophage to aggravate chordoma progression via the IER2/GMFG/ITGB1 axis, which may be targeted therapeutically in future.
Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
PCT No. PCT/HU83/00052 Sec. 371 Date Jun. 7, 1984 Sec. 102(e) Date Jun. 7, 1984 PCT Filed Oct. 7, 1983 PCT Pub. No. WO84/01502 PCT Pub. Date Apr. 26, 1984.The invention relates to contraceptive vaginal tablets as well as to a process for preparing them. The tablets of the invention have the following composition: 0.2 to 3 parts by weight of boric acid, 10 to 20 parts by weight of tartaric acid, 1 to 2 parts by weight of vitamin K3-sodium bisulfite adduct, 0.8 to 1.2 parts by weight of polyvinyl pyrrolidone, 2 to 5 parts by weight of magnesium stearate, 8 to 12 parts by weight of carboxymethyl cellulose, 8 to 12 parts by weight of lactose and 50 to 65 parts by weight of microcrystalline cellulose. The vaginal tablets contain preferably 5 to 10 mg of vitamin K3-sodium bisulfite adduct and have a total weight of 500 mg. The tablets of the invention are prepared preferably in such way that the boric acid, the tartaric acid and the vitamin K3-sodium bisulfite adduct, as well as the polyvinyl pyrrolidone, the magnesium stearate, the carboxymethyl cellulose, the lactose and the microcrystalline cellulose are homogenized separately to powder mixtures thereafter the powder mixtures are mixed and pressed to tablets. The tablets should be wetted and put into the back-vaginal fornix 10 minutes before the coitus.
Radical prostatectomy (RP) alone has traditionally been considered insufficient for patients with high-risk localized prostate cancer (HRPC) owing to the frequent need for adjuvant salvage radiotherapy or androgen deprivation therapy (ADT) following surgery. Previously, systemic therapy, such as ADT, was the standard treatment for metastatic prostate cancer (PC) patients; RP was not considered viable for these patients. However, since 2015, there has been a recognition that metastatic PC patients can be categorized based on the extent of their metastases, leading to the consideration of RP for some metastatic cases. In recent years, the concept of cytoreductive RP has gained traction; studies suggest that it may improve survival rates in metastatic PC patients through mechanisms, such as tumor debulking and enhancement of the immune response. A meta-analysis of retrospective studies has shown that cytoreductive RP is associated with higher cancer-specific survival rates at 1-year, 3-year, and 5-year intervals compared with systemic therapy alone. In our study, which followed HRPC and oligometastatic PC patients for an average of 46 months, we observed biochemical recurrence in 17.8% of HRPC and 13% of oligometastatic patients, with overall survival rates of 96.4% and 87%, respectively. Although prospective or randomized studies are still lacking, current retrospective studies, including our own, suggest promising outcomes for RP in HRPC and oligometastatic patients. With the increasing prevalence of robotic surgery, improved pelvic anatomy observation, and growing surgical confidence, the realization of prospective randomized study results may not be far off.
The Velphoro drug substance is a mixture of polynuclear iron(III)-oxyhydroxide, sucrose, and starches. The active moiety of Velphoro, polynuclear iron(III)-oxyhydroxide, is practically insoluble and cannot be absorbed.

Velphoro chewable tablets for oral use are brown, circular, bi-planar, and are embossed with “PA 500” on 1 side. Each tablet of Velphoro contains 500 mg iron (in 2,500 mg sucroferric oxyhydroxide). One tablet is equivalent to approximately 1.4 g of carbohydrates (750 mg sucrose and 700 mg starches as potato starch and pregelatinized maize starch). The inactive ingredients are berry flavor, neohesperidin dihydrochalcone, magnesium stearate, and silica (colloidal, anhydrous).
PROBLEM TO BE SOLVED: To obtain a new compound which exits in a form of racemic mixture or optical isomer and is useful for treatment of disorders in which involvement of serotoninergic system is confirmed, e.g. mental disorders, etc. SOLUTION: This compound is represented by formula I [(n) is 1 or 2; Ar is a group of formula II (X is H or F); R is H, a 1-5C alkyl or a 1-5C aralkyl; E is H or methyl; X1 to X4 are each H, a halogen, a 1-5C alkyl, a 1-5C alkoxy, etc.], specifically 1-(2,3-dihydro[1,4]-benzodioxin-5-yl)-4-[N-(indane-2-yl) amino]piperidine or its dibasic acid salt, etc. Furthermore, the compound is preferably obtained by reacting a compound of formula III (L is a reactive group) with a compound of formula IV, e.g. in methylisobutyl ketone in the presence of an alkali metal carbonate such as sodium carbonate.
Calcium oxalate (CaOx) kidney stones may be associated with urinary tract infections (UTIs). However, the mechanisms for this association are not well-established. The objective of this study was to investigate the effect of oxalate on immunity and UTI development in vivo. Female Sprague-Dawley rats were fed a control diet for 3 days before continuing this diet or starting a 5% Hydroxy-L-proline diet (HLP; oxalate precursor) for 7 days. Rats were subsequently infected transurethrally with Uropathogenic E. coli (UPEC, a bacterium that causes UTI) and sacrificed 3 days later. Urine, blood, kidney, and bladder samples were collected. Urinary oxalate levels, renal CaOx crystal deposition, inflammatory markers, and the bacterial load were assessed using ion chromatography-mass spectrometry, immunohistochemistry, qRT-PCR, western blotting, enzyme-linked immunosorbent assays, or colony forming unit assays. Animals fed HLP and infected with UPEC had a significant increase in urinary oxalate levels, renal CaOx deposition, pro-inflammatory macrophages, pro-inflammatory cytokines, and bacterial loads compared to animals fed the control diet with UPEC infection. In addition, HLP-fed animals had significantly reduced anti-inflammatory renal macrophages and anti-inflammatory cytokine levels in their plasma, urine, and kidneys. These findings suggest that oxalate may play a novel role in the propagation of UTI development.